Penn spinout Verismo Therapeutics, co-founded by Dr. Michael Milone and Dr. Donald Siegel, which focuses on a paradigm-shifting cell therapy for solid tumors, has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310. This treatment targets relapsed or refractory B-cell non-Hodgkin lymphomas (B-cell NHL). SynKIR-310 employs Verismo’s KIR-CAR platform, which uses NK cell-derived signaling to enhance T cell function and has the potential to combat both solid and blood cancers. Since its inception in 2020, Verismo has raised $50 million in company financing and established a research center in Philadelphia to advance its innovative therapies. Read more here.